Modality
Radioligand
MOA
WEE1i
Target
PD-1
Pathway
Amyloid
Prostate Ca
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
Mar 2019
→ Jan 2031
Phase 3Current
NCT03445931
312 pts·Prostate Ca
2025-12→2027-10·Terminated
NCT06339945
1,160 pts·Prostate Ca
2019-03→2027-05·Not yet recruiting
NCT04061449
1,304 pts·Prostate Ca
2023-02→TBD·Active
+1 more trial
4,794 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-05-191.1y awayPh3 Readout· Prostate Ca
2027-10-011.5y awayPh3 Readout· Prostate Ca
2031-01-114.8y awayPh3 Readout· Prostate Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Not yet…
P3
Active
P3
Not yet…
P3
Termina…
Catalysts
Ph3 Readout
2027-05-19 · 1.1y away
Prostate Ca
Ph3 Readout
2027-10-01 · 1.5y away
Prostate Ca
Ph3 Readout
2031-01-11 · 4.8y away
Prostate Ca
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03445931 | Phase 3 | Prostate Ca | Terminated | 312 | PFS |
| NCT06339945 | Phase 3 | Prostate Ca | Not yet recr... | 1160 | MRD |
| NCT04061449 | Phase 3 | Prostate Ca | Active | 1304 | PFS |
| NCT06580996 | Phase 3 | Prostate Ca | Not yet recr... | 2018 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |